



Patient Name	Gender	DOB	Phone
Address		Medicare #	Pension #

EXAMINATION

Clinical Notes

Primary Disease Site:.....
 Histopathology:.....
 Surgery Type:.....
 Chemotherapy: Last:.....Next:.....
 Radiotherapy: Last:.....Next:.....
 Previous PET Scan: Y / N Location:.....

Please tick one only (Medicare criteria on reverse)

Medicare Eligible PET Examinations with Diagnostic CT Brain, Neck, Chest, Abdomen and Pelvis, with IV Contrast for the following indication:

- | | | |
|--------------------------|--|-------------------------|
| <input type="checkbox"/> | BREAST CANCER, Stage III | (61524 + 56807 + 56001) |
| <input type="checkbox"/> | BREAST CANCER, suspected metastatic or recurrent | (61525 + 56807 + 56001) |
| <input type="checkbox"/> | SOLITARY PULMONARY NODULE | (61523 + 56807 + 56001) |
| <input type="checkbox"/> | NON-SMALL CELL LUNG CANCER, staging | (61529 + 56807 + 56001) |
| <input type="checkbox"/> | HL or NHL, initial staging | (61620 + 56807 + 56001) |
| <input type="checkbox"/> | HL or NHL, assess response to first line therapy | (61622 + 56807 + 56001) |
| <input type="checkbox"/> | HL or NHL, restaging | (61628 + 56807 + 56001) |
| <input type="checkbox"/> | HL or NHL, assess response to second line chemo | (61632 + 56807 + 56001) |
| <input type="checkbox"/> | HEAD and NECK CANCER, staging | (61598 + 56807 + 56001) |
| <input type="checkbox"/> | HEAD and NECK CANCER, suspected residual cancer | (61604 + 56807 + 56001) |
| <input type="checkbox"/> | METASTATIC SCC | (61610 + 56807 + 56001) |
| <input type="checkbox"/> | MELANOMA | (61553 + 56807 + 56001) |
| <input type="checkbox"/> | COLORECTAL CARCINOMA | (61541 + 56807 + 56001) |
| <input type="checkbox"/> | OESOPHAGEAL or GEJ CARCINOMA | (61577 + 56807 + 56001) |
| <input type="checkbox"/> | OVARIAN CARCINOMA | (61565 + 56807 + 56001) |
| <input type="checkbox"/> | UTERINE CERVIX CARCINOMA, primary staging | (61571 + 56807 + 56001) |
| <input type="checkbox"/> | UTERINE CERVIX CARCINOMA, recurrent cancer for staging | (61575 + 56807 + 56001) |
| <input type="checkbox"/> | SARCOMA, initial staging | (61640 + 56807 + 56001) |
| <input type="checkbox"/> | SARCOMA, suspected residual or recurrent | (61646 + 56807 + 56001) |
| <input type="checkbox"/> | ⁶⁸ Ga - DOTA for evaluation of NETs | (61647 + 56807 + 56001) |

FDG PET Examination with Diagnostic CT Brain with IV contrast for the following indication:

- | | | |
|--------------------------|--|-----------------|
| <input type="checkbox"/> | MALIGNANT BRAIN TUMOUR | (61538 + 56007) |
| <input type="checkbox"/> | REFRACTORY EPILEPSY which is being evaluated for surgery | (61559 + 56007) |

Other PET Examinations with Diagnostic CT Brain, Neck, Chest, Abdomen and Pelvis, with IV Contrast for the following indication:

- | | | |
|--------------------------|--|-------------------|
| <input type="checkbox"/> | PSMA for evaluation of prostate cancer | (+ 56807 + 56001) |
| <input type="checkbox"/> | ⁶⁸ Ga - DOTA for evaluation of NETs | (+ 56807 + 56001) |
| <input type="checkbox"/> | Any other UNFUNDED PET | (+ 56807 + 56001) |

Diagnostic CT - please indicate if a Diagnostic CT is not required

Please advise if the patient is: Diabetic | Renal Function Impaired | Pregnant | Breastfeeding | Infection Precaution

Consultation at time of examination requested with doctor:.....

REQUESTING PRACTITIONER

Practitioner name, provider number, address, phone, fax

Practitioner signature and date

RESULTS

EMERGENCY | Film | Phone | Faxam/pm | No.

Copy reports to:



For appointments please phone:

1300 788 508

Garran

Brindabella Specialist Centre

5 Dann Close

Fax: 6203 2111

Date Time Preparation

**PLEASE BRING RELEVANT
FILMS AND IMAGES TO
YOUR APPOINTMENT.**

Some examinations require special preparations, please check when making your appointment. Your practitioner has recommended that you use CIG. You may choose another provider but please check with your practitioner first.

Referring for PET/CT

Medicare Eligible PET Examinations with Diagnostic CT Brain, Neck, Chest, Abdomen and Pelvis, with IV Contrast for the following indication:

- BREAST CANCER, Stage III, Whole body FDG PET study performed for the staging of locally advanced (Stage III) breast cancer in a patient considered potentially suitable for active therapy. (61524 + 56807 + 56001)
- BREAST CANCER, Whole body FDG PET study performed for the evaluation of suspected metastatic or suspected locally or regionally recurrent breast carcinoma in a patient considered suitable for active therapy. (61525 + 56807 + 56001)
- SOLITARY PULMONARY NODULE evaluation, Whole body FDG PET study, performed for evaluation of a solitary pulmonary nodule where the lesion is considered unsuitable for transthoracic fine needle aspiration biopsy, or for which an attempt at pathological characterisation has failed. (61523 + 56807 + 56001)
- NON-SMALL CELL LUNG CANCER, Whole body FDG PET study, performed for the staging of proven non-small cell lung cancer, where curative surgery or radiotherapy is planned. (61529 + 56807 + 56001)
- HL or NHL, Whole body FDG PET study for the initial staging of newly diagnosed or previously untreated Hodgkin's or non-Hodgkin's lymphoma. (61620 + 56807 + 56001)
- HL or NHL, Whole body FDG PET study to assess response to first line therapy either during treatment or within three months of completing definitive first line treatment for Hodgkin's or non-Hodgkin's lymphoma. (61622 + 56807 + 56001)
- HL or NHL, Whole body FDG PET study for restaging following confirmation of recurrence of Hodgkin's or non-Hodgkin's lymphoma. (61628 + 56807 + 56001)
- HL or NHL, Whole body FDG PET study to assess response to second-line chemotherapy when stem cell transplantation is being considered, for Hodgkin's or non-Hodgkin's lymphoma. (61632 + 56807 + 56001)
- HEAD and NECK CANCER, Whole body FDG PET study performed for the staging of biopsy-proven newly diagnosed or recurrent head and neck cancer. (61598 + 56807 + 56001)
- HEAD and NECK CANCER, Whole body FDG PET study performed for the evaluation of patients with suspected residual head and neck cancer after definitive treatment, and who are suitable for active therapy. (61604 + 56807 + 56001)
- METASTATIC SCC, Whole body FDG PET study performed for the evaluation of metastatic squamous cell carcinoma of unknown primary site involving cervical nodes. (61610 + 56807 + 56001)
- MELANOMA, Whole body FDG PET study, following initial therapy, performed for the evaluation of suspected metastatic or recurrent malignant melanoma in patients considered suitable for active therapy. (61553 + 56807 + 56001)
- COLORECTAL CARCINOMA, Whole body FDG PET study, following initial therapy, for the evaluation of suspected residual, metastatic or recurrent colorectal carcinoma in patients considered suitable for active therapy. (61541 + 56807 + 56001)
- OESOPHAGEAL or GEJ CARCINOMA, Whole body FDG PET study, performed for the staging of proven oesophageal or GEJ carcinoma, in patients considered suitable for active therapy. (61577 + 56807 + 56001)
- OVARIAN CARCINOMA, Whole body FDG PET study, following initial therapy, performed for the evaluation of suspected residual, metastatic or recurrent ovarian carcinoma in patients considered suitable for active therapy. (61565 + 56807 + 56001)
- UTERINE CERVIX CARCINOMA, Whole body FDG PET study, for the further primary staging of patients with histologically proven carcinoma of the uterine cervix, at FIGO stage IB2 or greater by conventional staging, prior to planned radical radiation therapy or combined modality therapy with curative intent. (61571 + 56807 + 56001)
- UTERINE CERVIX CARCINOMA, Whole body FDG PET study, for the further staging of patients with confirmed local recurrence of carcinoma of the uterine cervix considered suitable for salvage pelvic chemoradiotherapy or pelvic exenteration with curative intent. (61575 + 56807 + 56001)
- SARCOMA, Whole body FDG PET study for initial staging of patients with biopsy-proven bone or soft tissue sarcoma (excluding gastrointestinal stromal tumour) considered by conventional staging to be potentially curable. (61640 + 56807 + 56001)
- SARCOMA, Whole body FDG PET study for the evaluation of patients with suspected residual or recurrent sarcoma (excluding gastrointestinal stromal tumour) after the initial course of definitive therapy to determine suitability for subsequent therapy with curative intent. (61646 + 56807 + 56001)
- ⁶⁸Ga - DOTA, Whole body PET study if: a) a gastro-entero-pancreatic neuroendocrine tumour is suspected on the basis of biochemical evidence with negative or equivocal conventional imaging; or
b) both (i) a surgical amenable gastro-entero-pancreatic neuroendocrine tumour has been identified on the basis of conventional techniques; and (ii) the study is for excluding additional disease sites. (61647 + 56807 + 56001)

FDG PET Examination with Diagnostic CT Brain with IV contrast for the following indication:

- MALIGNANT BRAIN TUMOUR, FDG PET study of the brain for evaluation of suspected residual or recurrent malignant brain tumour based on anatomical imaging findings, after definitive therapy (or during ongoing chemotherapy) in patients who are considered suitable for further active therapy. (61538 + 56007)
- REFRACTORY EPILEPSY, FDG PET study of the brain, performed for the evaluation of refractory epilepsy which is being evaluated for surgery. (61559 + 56007)

Other PET Examinations with Diagnostic CT Brain, Neck, Chest, Abdomen and Pelvis, with IV Contrast for the following indication:

- PSMA for evaluation of prostate cancer (+ 56807 + 56001)
- ⁶⁸Ga - DOTA for evaluation of NETs (+ 56807 + 56001)
- Any other UNFUNDED PET scan (+ 56807 + 56001)

PRIVACY CONSENT Canberra Imaging Group (ABN 43 450 532 159) and its related entities, including ACT X-Ray Services Pty Ltd (ABN 93 245 601 531) (we, us and our) collect personal information about you (including personal details, patient reports, x-rays and other medical images) for the purpose of providing you with health and imaging services. We may also disclose your personal information to your treating team, which may include the practitioner who referred you to us, or other practitioners, including medical specialists, practitioners (including allied health professionals) from which you seek a second opinion, or, if you have switched General Practitioners (GP), to your new GP (your treating team). If you do not provide all necessary information, we may not be able to provide our services, or may be limited in our capacity to provide them. Other purposes for which we may collect your personal information include for billing; for professional accreditation, quality assurance, or clinical auditing to respond to any accident, complaint or claim, where required or authorised by law; and otherwise to run our business. Apart from disclosing your personal information to health professionals involved in your care, we also may disclose your personal information to Medicare, the Department of Veterans Affairs and private health insurers; medical defence organisations and complaints handling bodies; our service providers, including IT professionals; and our professional advisors. We disclose your personal information to recipients located outside of Australia. Our privacy policy at www.canberraimaging.com.au/privacy-policy/ provides more detail about our approach to handling personal information, including how to access and correct your personal information stored by us, and our complaints handling procedures. By proceeding with the requested examination you consent to us handling your personal information in the manner outlined above. If you have any questions or concerns please contact our Patient Bookings Service on 1300 788 508.